BioXcel Therapeutics, Inc. (BTAI)
BioXcel Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
BioXcel Therapeutics, Inc. (BTAI) is a Biotechnology company based in US with a market capitalization of $37.1M. Revenue declined 71.7% year-over-year and free cash flow was negative at -$57.6M. This page tracks BTAI's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 37 employees · IPO Mar 8, 2018
Valuation
Valuation & price
$1.14as of May 17, 2026· -83.2% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
—
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$37.1M
Market cap
-71.7%
Revenue growth (YoY)
74.5%
Gross margin
-$57.6M
Free cash flow (USD)
$81.2M
Net debt
381.6%
Share dilution
0/4
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2022 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
4
Insider sells · 90 days
Earnings
Last reported: May 15, 2026 (EPS $-0.54)
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- Insider sellMay 22, 2026Filing
Insider Sell $21K · 10b5-1 PlanMehta Vimal · Director, CEO and President · $21.1K
- Insider sellMay 22, 2026Filing
Insider Sell $7K · 10b5-1 PlanSteinhart Richard I · Chief Financial Officer · $7.4K
- Insider sellMay 22, 2026Filing
Insider Sell $7K · 10b5-1 PlanRodriguez Javier · See Remarks · $7.1K
- Insider sellMay 22, 2026Filing
Insider Sell $7K · 10b5-1 PlanYocca Frank · Chief Scientific Officer · $7.4K
- Quarterly reportMay 15, 2026Filing
10-Q Filed
- 8-K eventMay 15, 2026Filing
Business Update and Financial Results
- 8-K eventApr 17, 2026Filing
Registration Rights Agreement
- 8-K eventApr 1, 2026Filing
FDA Application Accepted
Questions
Frequently asked questions
What is BioXcel Therapeutics, Inc.'s market cap?
BioXcel Therapeutics, Inc. (BTAI) has a market capitalization of $37.1M.
What is BTAI's P/E ratio?
A meaningful P/E ratio is not available for BTAI — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
When did BioXcel Therapeutics, Inc. last report earnings?
BTAI last reported earnings on May 15, 2026; the next date is not yet scheduled.
Are insiders buying BTAI stock?
SEC Form 4 filings show no open-market insider buys at BioXcel Therapeutics, Inc. in the last 90 days (4 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.